SCHEMBL791318

SCHEMBL791318

CC(=O)c1ccc2c(c1)c(-c1ccccc1)c1n2C(c2ccccc2)c2ccccc2-1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 4/20 0.37
FGFR1 P11362 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
FABP4 P15090 2/20 0.36
HPGD P15428 4/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
S100A4 P26447 1/20 0.35
P2RX3 P56373 1/20 0.33
AURKA O14965 1/20 0.33
DAPK3 O43293 1/20 0.33
JAK2 O60674 1/20 0.33
MAP4K4 O95819 1/20 0.33
ABL1 P00519 1/20 0.33
NTRK1 P04629 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
PRKACA P17612 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL772512 0.67 ALDH1A1 (0.37) ALDH1A1KDM4EKMT2AMAPK8
SCHEMBL774883 0.67 MAPK8 (0.39) ALDH1A1KDM4EMEN1KMT2AFABP4
SCHEMBL17955402 0.64 GABRA1 (0.32) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL12292122 0.63 GAA (0.34) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL8755335 0.62 MAPT (0.58) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL121659 0.61 L3MBTL1 (0.58) ALDH1A1KDM4EFGFR1MEN1KMT2A
SCHEMBL9511744 0.61 MAPT (0.57) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL24976100 0.60 KDM4E (0.52) ALDH1A1KDM4EMEN1KMT2AMAPT
SCHEMBL20783478 0.60 MAPT (0.73) ALDH1A1KDM4EMEN1KMT2AHPGD
SCHEMBL14176467 0.60 MAPT (0.61) ALDH1A1KDM4EMEN1KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 ALDH1A1 750/4885KDM4E 2725/4885FGFR1 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.